Болезнь Паркинсона

Список литературы

Основные статьи

Gelb, DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999 Jan;56(1):33-9. Аннотация

Kalra S, Grosset DG, Benamer HT. Differentiating vascular parkinsonism from idiopathic Parkinson's disease: a systematic review. Mov Disord. 2010 Jan 30;25(2):149-56. Аннотация

Miyasaki JM, Martin W, Suchowersky O, et al. Initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2002 Jan 8;58(1):11-7.Полный текст  Аннотация

Hart RG, Pearce LA, Ravina BM, et al. Neuroprotection trials in Parkinson's disease: systematic review. Mov Disord. 2009 Apr 15;24(5):647-54. Аннотация

Stowe R, Ives N, Clarke CE, et al. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson's disease patients with motor complications. Cochrane Database Syst Rev. 2010 Jul 7;(7):CD007166.Полный текст  Аннотация

Talati R, Reinhart K, Baker W, et al. Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors. Parkinsonism Relat Disord. 2009 Aug;15(7):500-5. Аннотация

Статьи, указанные как источники

1. De Rijk MC, Tzourio C, Breteler MMB, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON collaborative study. J Neurol Neurosurg Psychiatry. 1997 Jan;62(1):10-5.Полный текст  Аннотация

2. Zhang ZX, Roman GC. Worldwide occurrence of Parkinson's disease: an updated review. Neuroepidemiology. 1993;12(4):195-208. Аннотация

3. Bower JH, Maraganore DM, McDonnell SK, et al. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology. 1999 Apr 12;52(6):1214-20. Аннотация

4. Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci. 2003 Jun;991:1-14. Аннотация

5. Rosati G, Graniere E, Pinna L, et al. The risk of Parkinson disease in Mediterranean people. Neurology. 1980 Mar;30(3):250-5. Аннотация

6. Enders D, Balzer-Geldsetzer M, Riedel O, et al. Prevalence, duration and severity of Parkinson's disease in Germany: a combined meta-analysis from literature data and outpatient samples. Eur Neurol. 2017 Jul 27;78(3-4):128-36. Аннотация

7. GBD 2016 Parkinson's Disease Collaborators. Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018 Nov;17(11):939-53. Аннотация

8. Quinn N, Crtichley P, Marsden CD. Young onset Parkinson's disease. Mov Disord. 1987;2(2):73-91. Аннотация

9. Rajput AH, Offord KP, Beard CM, et al. Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol. 1984 Sep;16(3):278-82. Аннотация

10. de Rijk MC. Epidemiology of Parkinson's disease: the Rotterdam Study [PhD thesis]. Rotterdam, The Netherlands: Erasmus University; 1997.

11. Diamond SG, Markham CH, Hoehn MM, et al. An examination of male-female differences in progression and mortality of Parkinson's disease. Neurology. 1990 May;40(5):763-6. Аннотация

12. Pringsheim T, Jette N, Frolkis A, et al. The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov Disord. 2014 Nov;29(13):1583-90. Аннотация

13. Hirsch L, Jette N, Frolkis A, et al. The incidence of Parkinson's disease: a systematic review and meta-analysis. Neuroepidemiology. 2016;46(4):292-300.Полный текст  Аннотация

14. Georgiev D, Hamberg K, Hariz M, et al. Gender differences in Parkinson's disease: a clinical perspective. Acta Neurol Scand. 2017 Dec;136(6):570-84. Аннотация

15. McInerney-Leo A, Gwinn-Hardy K, Nussbaum RL. Prevalence of Parkinson's disease in populations of African ancestry: a review. J Natl Med Assoc. 2004 Jul;96(7):974-9. Аннотация

16. Tanner CM, Ottman R, Goldman SM, et al. Parkinson disease in twins: an etiologic study. JAMA. 1999 Jan 27;281(4):341-6.Полный текст  Аннотация

17. Fang J, Hou B, Liu H, et al. Association between SNCA rs2736990 polymorphism and Parkinson's disease: a meta-analysis. Neurosci Lett. 2017 Sep 29;658:102-7. Аннотация

18. Zhao H, Kong Z. Relationship between LRRK2 R1628P polymorphism and Parkinson's disease in Asian populations. Oncotarget. 2016 Jul 26;7(30):46890-8.Полный текст  Аннотация

19. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med. 2009 Oct 22;361(17):1651-61.Полный текст  Аннотация

20. Neumann J, Bras J, Deas E, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain. 009 Jul;132(Pt 7):1783-94.Полный текст  Аннотация

21. He T, Wang J, Wang X, et al. Association between PARK16 and Parkinson's disease: a meta-analysis. Neurosci Lett. 2017 Aug 12;657:179-88. Аннотация

22. Liu L, Zhang L, Guo L, et al. MTHFR C677T and A1298C polymorphisms may contribute to the risk of Parkinson's disease: a meta-analysis of 19 studies. Neurosci Lett. 2017 Oct 31;662:339-45. Аннотация

23. Fagan ES, Pihlstrøm L. Genetic risk factors for cognitive decline in Parkinson's disease: a review of the literature. Eur J Neurol. 2017 Apr;24(4):561-e20. Аннотация

24. Sayad M, Zouambia M, Chaouch M, et al. Greater improvement in LRRK2 G2019S patients undergoing subthalamic nucleus deep brain stimulation compared to non-mutation carriers. BMC Neurosci. 2016 Feb 1;17:6.Полный текст  Аннотация

25. Langston JW. The MPTP story. J Parkinsons Dis. 2017;7(s1):S11-S19.Полный текст  Аннотация

26. Bjorklund G, Stejskal V, Urbina MA, et al. Metals and Parkinson's disease: mechanisms and biochemical processes. Curr Med Chem. 2018;25(19):2198-214. Аннотация

27. Oueslati A, Ximerakis M, Vekrellis K. Protein transmission, seeding and degradation: key steps for alpha-synuclein prion-like propagation. Exp Neurobiol. 2014 Dec;23(4):324-36.Полный текст  Аннотация

28. Wichmann T, DeLong MR. Functional neuroanatomy of the basal ganglia in Parkinson's disease. Adv Neurol. 2003;91:9-18. Аннотация

29. Jankovic J, Ben-Arie L, Schwartz K, et al. Movement and reaction times and fine coordination tasks following pallidotomy. Mov Disord. 1999 Jan;14(1):57-62. Аннотация

30. Vingerhoets FJ, Schulzer M, Calne DB, et al. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol. 1997 Jan;41(1):58-64. Аннотация

31. Dostrovsky JO, Hutchinson WD, Lozano AM. The globus pallidus, deep brain stimulation and Parkinson's disease. Neuroscientist. 2002 Jun;8(3):284-90. Аннотация

32. Tatton WG, Lee RG. Evidence for abnormal long-loop reflexes in rigid Parkinsonian patients. Brain Res. 1975 Dec 26;100(3):671-6. Аннотация

33. Horak FB, Nutt JG, Nashner LM. Postural inflexibility in parkinsonism subjects. J Neurol Sci. 1992 Aug;111(1):46-58. Аннотация

34. Hedreen JC. Tyrosine hydroxylase-immunoreactive elements in the human globus pallidus and subthalamic nucleus. J Comp Neurol. 1999 Jul 5;409(3):400-10. Аннотация

35. Koller W, Pahwa R, Busenbark K, et al. High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. Ann Neurol. 1997 Sep;42(3):292-9. Аннотация

36. Lee RG, Stein RB. Resetting of tremor by mechanical perturbations: a comparison of essential tremor and parkinsonian tremor. Ann Neurol. 1981 Dec;10(6):523-31. Аннотация

37. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003 Mar-Apr;24(2):197-211. Аннотация

38. Braak H, de Vos RA, Bohl J, et al. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett. 2006 Mar 20;396(1):67-72. Аннотация

39. Bloch A, Probst A, Bissig H, et al. Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol Appl Neurobiol. 2006 Jun;32(3):284-95. Аннотация

40. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997 Jun 27;276(5321):2045-7. Аннотация

41. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998 Apr 9;392(6676):605-8. Аннотация

42. Leroy E, Boyer R, Auburger G, et al. The ubiquitin pathway in Parkinson's disease. Nature. 1998 Oct 1;395(6701):451-2. Аннотация

43. Langston JW, Ballard P, Tetrud JW, et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983 Feb 25;219(4587):979-80. Аннотация

44. Mena I, Marin O, Fuenzalida S, et al. Chronic manganese poisoning: Clinical pictures and manganese turnover. Neurology. 1967 Feb;17(2):128-36. Аннотация

45. Dekker MC, Giesbergen PC, Njajou OT, et al. Mutations in the hemochromatosis gene (HFE), Parkinson's disease and parkinsonism. Neurosci Lett. 2003 Sep 11;348(2):117-9. Аннотация

46. Marder K, Tang MX, Mejia H, et al. Risk of Parkinson's disease among first-degree relatives: a community-based study. Neurology. 1996 Jul;47(1):155-60. Аннотация

47. Nicoletti A, Vasta R, Mostile G, et al. Head trauma and Parkinson's disease: results from an Italian case-control study. Neurol Sci. 2017 Oct;38(10):1835-9. Аннотация

48. Jafari S, Etminan M, Aminzadeh F, et al. Head injury and risk of Parkinson disease: a systematic review and meta-analysis. Mov Disord. 2013 Aug;28(9):1222-9. Аннотация

49. Kenborg L, Rugbjerg K, Lee PC, et al. Head injury and risk for Parkinson disease: results from a Danish case-control study. Neurology. 2015 Mar 17;84(11):1098-103.Полный текст  Аннотация

50. Harris MA, Shen H, Marion SA, et al. Head injuries and Parkinson's disease in a case-control study. Occup Environ Med. 2013 Dec;70(12):839-44. Аннотация

51. Schoenberg BS. Environmental risk factors for Parkinson's disease: the epidemiologic evidence. Can J Neurol Sci. 1987 Aug;14(3 suppl):407-13. Аннотация

52. Goldman SM, Quinlan PJ, Ross GW, et al. Solvent exposures and Parkinson disease risk in twins. Ann Neurol. 2012 Jun;71(6):776-84. Аннотация

53. Gorell JM, Johnson CC, Rybicki BA, et al. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology. 1998 May;50(5):1346-50. Аннотация

54. Bocchetta A, Corsini GU. Parkinson's disease and pesticides. Lancet. 1986 Nov 15;2(8516):1163. Аннотация

55. Sanchez-Ramos JR, Hefti F, Weiner WJ. Paraquat and Parkinson's disease. Neurology. 1987 Apr;37(4):728. Аннотация

56. Barbosa ER, Leiros da Costa MD, Bacheschi LA, et al. Parkinsonism after glycine-derivate exposure. Mov Disord. 2001 May;16(3):565-8. Аннотация

57. Schulte PA, Burnett CA, Boeniger MF, et al. Neurodegenerative diseases: occupational occurrence and potential risk factors, 1982 through 1991. Am J Public Health. 1996 Sep;86(9):1281-8.Полный текст  Аннотация

58. Herishanu YO, Medvedovski M, Goldsmith JR, et al. A case-control study of Parkinson's disease in urban population of southern Israel. Can J Neurol Sci. 2001 May;28(2):144-7. Аннотация

59. Fall PA, Fredrikson M, Axelson O, et al. Nutritional and occupational factors influencing the risk of Parkinson's disease: a case-control study in southeastern Sweden. Mov Disord. 1999 Jan;14(1):28-37. Аннотация

60. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015 Oct;30(12):1591-601. Аннотация

61. Postuma RB, Poewe W, Litvan I, et al. Validation of the MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2018 Oct;33(10):1601-8. Аннотация

62. Schrag A, Barone P, Brown RG, et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord. 2007 Jun 15;22(8):1077-92.Полный текст  Аннотация

63. Lawton M, Hu MT, Baig F, et al. Equating scores of the University of Pennsylvania Smell Identification Test and Sniffin' Sticks test in patients with Parkinson's disease. Parkinsonism Relat Disord. 2016 Dec;33:96-101.Полный текст  Аннотация

64. Nielsen T, Jensen MB, Stenager E, et al. The use of olfactory testing when diagnosing Parkinson's disease - a systematic review. Dan Med J. 2018 May;65(5):A5481. Аннотация

65. Ponsen MM, Stoffers D, Booij J, et al. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol. 2004 Aug;56(2):173-81. Аннотация

66. Kägi G, Bhatia KP, Tolosa E. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry. 2010 Jan;81(1):5-12. Аннотация

67. Berardelli A, Wenning GK, Antonini A, et al. EFNS/MDS-ES/ENS recommendations for the diagnosis of Parkinson's disease. Eur J Neurol. 2013 Jan;20(1):16-34.Полный текст  Аннотация

68. Chang D, Nalls MA, Hallgrímsdóttir IB, et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci. Nat Genet. 2017 Oct;49(10):1511-6.Полный текст  Аннотация

69. Strickland D. Rural environment and Parkinson's disease. In: Ebadi M, Pfeiffer R, eds. Parkinson's disease. Boca Raton, FL: CRC Press; 2005:63-71.

70. Gelb, DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999 Jan;56(1):33-9. Аннотация

71. Bhatia KP, Bain P, Bajaj N, et al. Consensus statement on the classification of tremors. from the task force on tremor of the International Parkinson and Movement Disorder Society. Mov Disord. 2018 Jan;33(1):75-87.Полный текст  Аннотация

72. Deuschl G, Bain P, Brin M; Ad Hoc Scientific Committee. Consensus statement of the Movement Disorder Society on tremor. Mov Disord. 1998;13(suppl 3):2-23. Аннотация

73. Reiter E, Mueller C, Pinter B, et al. Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative parkinsonism. Mov Disord. 2015 Jul;30(8):1068-76. Аннотация

74. Mahlknecht P, Krismer F, Poewe W, et al. Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease. Mov Disord. 2017 Apr;32(4):619-23. Аннотация

75. Kalra S, Grosset DG, Benamer HT. Differentiating vascular parkinsonism from idiopathic Parkinson's disease: a systematic review. Mov Disord. 2010 Jan 30;25(2):149-56. Аннотация

76. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology. 2001 Oct 23;57(8):1497-9. Аннотация

77. Doty RL, Shaman P, Kimmelman CP, et al. University of Pennsylvania smell identification test: a rapid quantitative olfactory function test for the clinic. Laryngoscope. 1984 Feb;94(2 Pt 1):176-8. Аннотация

78. Doty RL, Deems DA, Stellar S. Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology. 1988 Aug;38(8):1237-44. Аннотация

79. Walter U, Niehaus L, Probst T, et al. Brain parenchyma sonography discriminates Parkinson's disease and atypical parkinsonian syndromes. Neurology. 2003 Jan 14;60(1):74-7. Аннотация

80. Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017 Jun;32(6):853-64.Полный текст  Аннотация

81. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy: a heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol. 1964 Apr;10:333-59. Аннотация

82. Wenning GK, Ben-Shlomo Y, Hughes A, et al. What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease? J Neurol Neurosurg Psychiatry. 2000 Apr;68(4):434-40.Полный текст  Аннотация

83. Zupancic M, Mahajan A, Handa K. Dementia with Lewy bodies: diagnosis and management for primary care providers. Prim Care Companion CNS Disord. 2011;13:PCC.11r01190.Полный текст  Аннотация

84. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4.Полный текст  Аннотация

85. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15;23(15):2129-70.Полный текст  Аннотация

86. Miyasaki JM, Martin W, Suchowersky O, et al. Initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2002 Jan 8;58(1):11-7.Полный текст  Аннотация

87. Clarke CE, Patel S, Ives N, et al. Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops? Mov Disord. 2011 Jun;26(7):1187-93. Аннотация

88. Hart RG, Pearce LA, Ravina BM, et al. Neuroprotection trials in Parkinson's disease: systematic review. Mov Disord. 2009 Apr 15;24(5):647-54. Аннотация

89. Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and Movement Disorder Society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2018 Aug;33(8):1248-66. Аннотация

90. Schapira AH, McDermott MP, Barone P, et al. Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet Neurol. 2013 Aug;12(8):747-55.Полный текст  Аннотация

91. Rascol O, Hauser RA, Stocchi F, et al. Long-term effects of rasagiline and the natural history of treated Parkinson's disease. Mov Disord. 2016 Oct;31(10):1489-96. Аннотация

92. Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. Mov Disord. 2019 Feb;34(2):180-98. Аннотация

93. Weintraub D, Moberg PJ, Duda JE, et al. Effect of psychiatric and other non-motor symptoms on disability in Parkinson's disease. J Am Geriatr Soc. 2004 May;52(5):784-8. Аннотация

94. Chahine LM, Amara AW, Videnovic A. A systematic review of the literature on disorders of sleep and wakefulness in Parkinson's disease from 2005 to 2015. Sleep Med Rev. 2017 Oct;35:33-50.Полный текст  Аннотация

95. Baillon S, Dennis M, Lo N, et al. Screening for depression in Parkinson's disease: the performance of two screening questions. Age Ageing. 2014 Mar;43(2):200-5.Полный текст  Аннотация

96. Bega D, Wu SS, Pei Q, et al. Recognition and treatment of depressive symptoms in Parkinson's disease: the NPF Dataset. J Parkinsons Dis. 2014;4(4):639-43. Аннотация

97. Broen MP, Narayen NE, Kuijf ML, et al. Prevalence of anxiety in Parkinson's disease: a systematic review and meta-analysis. Mov Disord. 2016 Aug;31(8):1125-33. Аннотация

98. Lima LO, Scianni A, Rodrigues-de-Paula F. Progressive resistance exercise improves strength and physical performance in people with mild to moderate Parkinson's disease: a systematic review. J Physiother. 2013 Mar;59(1):7-13. Аннотация

99. Tomlinson CL, Patel S, Meek C, et al. Physiotherapy versus placebo or no intervention in Parkinson's disease. Cochrane Database Syst Rev. 2013 Sep 10;(9):CD002817.Полный текст  Аннотация

100. da Silva FC, Iop RDR, de Oliveira LC, et al. Effects of physical exercise programs on cognitive function in Parkinson's disease patients: a systematic review of randomized controlled trials of the last 10 years. PLoS One. 2018 Feb 27;13(2):e0193113.Полный текст  Аннотация

101. Corcos DM, Robichaud JA, David FJ, et al. A two-year randomized controlled trial of progressive resistance exercise for Parkinson's disease. Mov Disord. 2013 Aug;28(9):1230-40.Полный текст  Аннотация

102. Bega D, Gonzalez-Latapi P, Zadikoff C, et al. A review of the clinical evidence for complementary and alternative therapies in Parkinson's disease. Curr Treat Options Neurol. 2014 Oct;16(10):314. Аннотация

103. Li F, Harmer P, Fitzgerald K, et al. Tai chi and postural stability in patients with Parkinson's disease. N Engl J Med. 2012 Feb 9;366(6):511-9.Полный текст  Аннотация

104. Gao Q, Leung A, Yang Y, et al. Effects of Tai Chi on balance and fall prevention in Parkinson's disease: a randomized controlled trial. Clin Rehabil. 2014 Aug;28(8):748-53. Аннотация

105. Song R, Grabowska W, Park M, et al. The impact of Tai Chi and Qigong mind-body exercises on motor and non-motor function and quality of life in Parkinson's disease: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2017 Aug;41:3-13.Полный текст  Аннотация

106. Hackney ME, Earhart GM, et al. Effects of dance on movement control in Parkinson's disease: a comparison of Argentine tango and American ballroom. J Rehabil Med. 2009 May;41(6):475-81.Полный текст  Аннотация

107. Dos Santos Delabary M, Komeroski IG, Monteiro EP, et al. Effects of dance practice on functional mobility, motor symptoms and quality of life in people with Parkinson's disease: a systematic review with meta-analysis. Aging Clin Exp Res. 2018 Jul;30(7):727-35. Аннотация

108. Ćwiękała-Lewis KJ, Gallek M, Taylor-Piliae RE. The effects of Tai Chi on physical function and well-being among persons with Parkinson's disease: a systematic review. J Bodyw Mov Ther. 2017 Apr;21(2):414-21. Аннотация

109. Allen NE, Sherrington C, Paul SS, et al. Balance and falls in Parkinson's disease: a meta-analysis of the effect of exercise and motor training. Mov Disord. 2011 Aug 1;26(9):1605-15. Аннотация

110. Rao AK. Enabling functional independence in Parkinson's disease: update on occupational therapy intervention. Mov Disord. 2010;25(suppl 1):S146-51. Аннотация

111. Lawrence BJ, Gasson N, Bucks RS, et al. Cognitive training and noninvasive brain stimulation for cognition in Parkinson's disease: a meta-analysis. Neurorehabil Neural Repair. 2017 Jul;31(7):597-608. Аннотация

112. Verschuur CVM, Suwijn SR, Boel JA, et al. Randomized delayed-start trial of levodopa in Parkinson's disease. N Engl J Med. 2019 Jan 24;380(4):315-24. Аннотация

113. Dezsi L, Vecsei L. Monoamine oxidase B inhibitors in Parkinson's disease. CNS Neurol Disord Drug Targets. 2017;16(4):425-39. Аннотация

114. Binde CD, Tvete IF, Gåsemyr J, et al. A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease. Br J Clin Pharmacol. 2018 Sep;84(9):1917-27.Полный текст  Аннотация

115. Zhou CQ, Li SS, Chen ZM, et al. Rotigotine transdermal patch in Parkinson's disease: a systematic review and meta-analysis. PLoS One. 2013 Jul 23;8(7):e69738.Полный текст  Аннотация

116. Chen F, Jin L, Nie Z. Safety and efficacy of rotigotine for treating Parkinson's disease: a meta-analysis of randomised controlled trials. J Pharm Pharm Sci. 2017;20(0):285-94. Аннотация

117. Guin D, Mishra MK, Talwar P, et al. A systematic review and integrative approach to decode the common molecular link between levodopa response and Parkinson's disease. BMC Med Genomics. 2017 Sep 19;10(1):56.Полный текст  Аннотация

118. Stowe R, Ives N, Clarke CE, et al. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson's disease patients with motor complications. Cochrane Database Syst Rev. 2010 Jul 7;(7):CD007166.Полный текст  Аннотация

119. Talati R, Reinhart K, Baker W, et al. Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors. Parkinsonism Relat Disord. 2009 Aug;15(7):500-5. Аннотация

120. Li J, Lou Z, Liu X, et al. Efficacy and Safety of Adjuvant Treatment with Entacapone in Advanced Parkinson's Disease with Motor Fluctuation: A Systematic Meta-Analysis. Eur Neurol. 2017;78(3-4):143-53.Полный текст  Аннотация

121. Ferreira JJ, Lees A, Rocha JF, et al. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016 Feb;15(2):154-65. Аннотация

122. Schapira AH, Fox SH, Hauser RA, et al. Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol. 2017 Feb 1;74(2):216-24. Аннотация

123. Hauser RA, Hsu A, Kell S, et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol. 2013 Apr;12(4):346-56. Аннотация

124. LeWitt PA, Huff FJ, Hauser RA, et al. Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease. Mov Disord. 2014 Jan;29(1):75-82. Аннотация

125. Stocchi F, Hsu A, Khanna S, et al. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients. Parkinsonism Relat Disord. 2014 Dec;20(12):1335-40.Полный текст  Аннотация

126. Lang AE, Houeto JL, Krack P, et al. Deep brain stimulation: preoperative issues. Mov Disord. 2006 Jun;21 (suppl 14):S171-96. Аннотация

127. Katzenschlager R, Poewe W, Rascol O, et al. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2018 Sep;17(9):749-59. Аннотация

128. Rughani A, Schwalb JM, Sidiropoulos C, et al. Congress of Neurological Surgeons systematic review and evidence-based guideline on subthalamic nucleus and globus pallidus internus deep brain stimulation for the treatment of patients with Parkinson's disease: executive summary. Neurosurgery. 2018 Jun 1;82(6):753-6.Полный текст  Аннотация

129. Williams A, Gill S, Varma T, et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol. 2010 Jun;9(6):581-91.Полный текст  Аннотация

130. National Medical Association. Deep brain stimulation better than best medical therapy for Parkinson disease. J Natl Med Assoc. 2009;101:490.

131. Schuepbach WM, Rau J, Knudsen K, et al; EARLYSTIM Study Group. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med. 2013 Feb 14;368(7):610-22.Полный текст  Аннотация

132. Suarez-Cedeno G, Suescun J, Schiess MC. Earlier intervention with deep brain stimulation for Parkinson's disease. Parkinsons Dis. 2017;2017:9358153.Полный текст  Аннотация

133. Follett KA, Weaver FM, Stern M, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med. 2010 Jun 3;362(22):2077-91. Аннотация

134. Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014 Feb;13(2):141-9. Аннотация

135. Fernandez HH, Standaert DG, Hauser RA, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord. 2015 Apr;30(4):500-9.Полный текст  Аннотация

136. Wirdefeldt K, Odin P, Nyholm D. Levodopa-carbidopa intestinal gel in patients with Parkinson's disease: a systematic review. CNS Drugs. 2016 May;30(5):381-404. Аннотация

137. Mínguez-Mínguez S, Solís-García Del Pozo J, Jordán J. Rasagiline in Parkinson's disease: a review based on meta-analysis of clinical data. Pharmacol Res. 2013 Aug;74:78-86. Аннотация

138. Chang Y, Wang LB, Li D, et al. Efficacy of rasagiline for the treatment of Parkinson's disease: an updated meta-analysis. Ann Med. 2017 Aug;49(5):421-34. Аннотация

139. European Medicines Agency. CMDh confirms recommendations on restricting use of domperidone-containing medicines. April 2014 [internet publication].Полный текст

140. Lew MF, Somogyi M, McCague K, et al. Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off. Int J Neurosci. 2011 Nov;121(11):605-13. Аннотация

141. Moore SF, Guzman NV, Mason SL, et al. Which patients with Parkinson's disease participate in clinical trials? One centre's experiences with a new cell based therapy trial (TRANSEURO). J Parkinsons Dis. 2014;4(4):671-6. Аннотация

142. Palfi S, Gurruchaga JM, Ralph GS, et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. Lancet. 2014 Mar 29;383(9923):1138-46. Аннотация

143. Palfi S, Gurruchaga JM, Lepetit H, et al. Long-term follow-up of a phase I/II study of ProSavin, a lentiviral vector gene therapy for Parkinson's disease. Hum Gene Ther Clin Dev. 2018 Sep;29(3):148-55.Полный текст  Аннотация

144. Marks WJ Jr, Baumann TL, Bartus RT. Long-term safety of patients with Parkinson's disease receiving rAAV2-neurturin (CERE-120) gene transfer. Hum Gene Ther. 2016 Jul;27(7):522-7. Аннотация

145. Mizuno Y, Kondo T; Japanese Istradefylline Study Group. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease. Mov Disord. 2013 Jul;28(8):1138-41.Полный текст  Аннотация

146. Kondo T, Mizuno Y, Japanese Istradefylline Study Group. A long-term study of istradefylline safety and efficacy in patients with Parkinson disease. Clin Neuropharmacol. 2015 Mar-Apr;38(2):41-6. Аннотация

147. Pourcher E, Fernandez HH, Stacy M, et al. Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study. Parkinsonism Relat Disord. 2012 Feb;18(2):178-84. Аннотация

148. Tison F, Keywood C, Wakefield M, et al. A phase 2A trial of the novel mGluR5-negative allosteric modulator dipraglurant for levodopa-induced dyskinesia in Parkinson's disease. Mov Disord. 2016 Sep;31(9):1373-80. Аннотация

149. Berk S, Greco BL, Biglan K, et al. Increasing efficiency of recruitment in early Parkinson's disease trials: a case study examination of the STEADY-PD III trial. J Parkinsons Dis. 2017;7(4):685-93.Полный текст  Аннотация

150. Parkinson Study Group. Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD). Mov Disord. 2013 Nov;28(13):1823-31. Аннотация

151. Schwarzschild MA, Ascherio A, Beal MF, et al.; Parkinson Study Group SURE-PD Investigators. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014 Feb;71(2):141-50. Аннотация

152. LeWitt PA, Hauser RA, Pahwa R, et al. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 2019 Feb;18(2):145-54. Аннотация

153. Kaufmann H, Freeman R, Biaggioni I, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology. 2014 Jul 22;83(4):328-35.Полный текст  Аннотация

154. Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord. 2008 Apr 30;23(6):837-44.Полный текст  Аннотация

155. Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol. 2001 Oct;58(10):1611-5.Полный текст  Аннотация

156. Marras C, McDermott MP, Marek K, et al. Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts. Mov Disord. 2011 Mar;26(4):608-13. Аннотация

157. Velseboer DC, Broeders M, Post B, et al. Prognostic factors of motor impairment, disability, and quality of life in newly diagnosed PD. Neurology. 2013 Feb 12;80(7):627-33. Аннотация

158. Kelberman MA, Vazey EM. New pharmacological approaches to treating non-motor symptoms of Parkinson's disease. Curr Pharmacol Rep. 2016 Dec;2(6):253-61.Полный текст  Аннотация

159. Dubois B, Tolosa E, Katzenschlager R, et al. Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord. 2012 Sep 1;27(10):1230-8. Аннотация

160. Rolinski M, Fox C, Maidment I, et al. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev. 2012 Mar 14;(3):CD006504.Полный текст  Аннотация

161. Eng ML, Welty TE. Management of hallucinations and psychosis in Parkinson's disease. Am J Geriatr Pharmacother. 2010 Aug;8(4):316-30. Аннотация

162. Wilby KJ, Johnson EG, Johnson HE, et al. Evidence-based review of pharmacotherapy used for Parkinson's disease psychosis. Ann Pharmacother. 2017 Aug;51(8):682-95. Аннотация

163. Iketani R, Kawasaki Y, Yamada H. Comparative utility of atypical antipsychotics for the treatment of psychosis in Parkinson's disease: a systematicv review and Bayesian network meta-analysis. Biol Pharm Bull. 2017;40(11):1976-82. Аннотация

164. Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014 Feb 8;383(9916):533-40. Аннотация

165. Kianirad Y, Simuni T. Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis. Expert Rev Clin Pharmacol. 2017 Nov;10(11):1161-8. Аннотация

166. Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010 May;67(5):589-95.Полный текст  Аннотация

167. Corvol JC, Artaud F, Cormier-Dequaire F, et al. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology. 2018 Jul 17;91(3):e189-e201.Полный текст  Аннотация

168. Knudsen K, Krogh K, Østergaard K, et al. Constipation in parkinson's disease: Subjective symptoms, objective markers, and new perspectives. Mov Disord. 2017 Jan;32(1):94-105. Аннотация

169. Stocchi F, Torti M. Constipation in Parkinson's disease. Int Rev Neurobiol. 2017 Jul 13;134:811-26. Аннотация

Использование этого контента попадает под действие нашего заявления об отказе от ответственности